Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma

被引：0

作者：

Tan, Carlyn Rose ^{[1
]}

Maclachlan, Kylee ^{[2
]}

Nemirovsky, David ^{[3
]}

Derkach, Andriy ^{[1
]}

Hultcrantz, Malin ^{[2
]}

Hassoun, Hani ^{[2
]}

Mailankody, Sham ^{[2
]}

Shah, Urvi ^{[2
]}

Patel, Dhwani ^{[1
]}

Shekarkhand, Tala ^{[1
]}

Rueda, Colin ^{[1
]}

Lahoud, Oscar ^{[1
]}

Shah, Gunjan ^{[1
]}

Scordo, Michael ^{[1
]}

Chung, David ^{[4
]}

Landau, Heather ^{[4
]}

Giralt, Sergio ^{[1
]}

Usmani, Saad ^{[1
]}

Lesokhin, Alexander ^{[1
]}

Korde, Neha ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant & Cellular Therapy, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P166

引用

页码：S127 / S127

页数：1

共 50 条

[1] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Maclachlan, Kylee H.
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Shekarkhand, Tala
Rueda, Colin
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander
Usmani, Saad Z.
BLOOD, 2023, 142
[2] Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Wang, Yuqi
Huan, Chen
Hanzhen, Zhang
Zhang, Shanshan
Yuan, Youhai
Feng, Ru
Wei, Yongqiang
Wei, Xiaolei
BLOOD, 2024, 144 : 7031 - 7031
[3] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Tan, Carlyn Rose
Derkach, Andriy
Nemirovsky, David
Ciardiello, Amanda
Diamond, Benjamin
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi
Maclachlan, Kylee
Patel, Dhwani
Lahoud, Oscar B. B.
Landau, Heather J. J.
Chung, David J. J.
Shah, Gunjan L. L.
Scordo, Michael
Giralt, Sergio A. A.
Lesokhin, Alexander
Usmani, Saad Z. Z.
Landgren, Ola
Korde, Neha
BLOOD CANCER JOURNAL, 2023, 13 (01)
[4] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Carlyn Rose Tan
Andriy Derkach
David Nemirovsky
Amanda Ciardiello
Benjamin Diamond
Malin Hultcrantz
Hani Hassoun
Sham Mailankody
Urvi Shah
Kylee Maclachlan
Dhwani Patel
Oscar B. Lahoud
Heather J. Landau
David J. Chung
Gunjan L. Shah
Michael Scordo
Sergio A. Giralt
Alexander Lesokhin
Saad Z. Usmani
Ola Landgren
Neha Korde
Blood Cancer Journal, 13
[5] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond L.
Wang, Jianping
de Boer, Carla
Deraedt, William
Weiss, Brendan M.
Schecter, Jordan M.
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
[6] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Sonneveld, Pieter
Dimopoulos, Meletios A.
Boccadoro, Mario
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Sureda Balari, Anna
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Silzle, Tobias
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Ahmadi, Tahamtan
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Rodriguez-Otero, Paula
Blade, Joan
Moreau, Philippe
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (04): : 301 - 313
[7] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Phuong-Dung, Liang
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Malave, Gabriella C.
Vossen, Alanna M.
Dingli, David
Go, Ronald S.
Warsame, Rahma M.
Kourelis, Taxiarchis
Hwa, Yi L.
Fonder, Amie
Hobbs, Miriam A.
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
BLOOD, 2020, 136
[8] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
Tan, Carlyn
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Patel, Dhwani
Maclachlan, Kylee H.
Lahoud, Oscar B.
Shah, Gunjan L.
Scordo, Michael
Chung, David J.
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander M.
Korde, Neha
Usmani, Saad
BLOOD, 2022, 140 : 1817 - 1819
[9] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Derman, Ben A.
Major, Ajay
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Alcantar, Luis
Libao, Bernadette M.
McIver, Amanda
Andreatos, Evangelia
Major, Sarah
Wolfe, Brittany
Gorski, Martha
Karrison, Theodore G.
Stefka, Andrew
Jakubowiak, Andrzej
BLOOD, 2021, 138
[10] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A.
Oriol, A.
Nahi, H.
San-Miguel, J.
Bahlis, N. J.
Usmani, S. Z.
Rabin, N.
Orlowski, R. Z.
Komarnicki, M.
Suzuki, K.
Plesner, T.
Yoon, S. -S.
Ben Yehuda, D.
Richardson, P. G.
Goldschmidt, H.
Reece, D.
Lisby, S.
Khokhar, N. Z.
O'Rourke, L.
Chiu, C.
Qin, X.
Guckert, M.
Ahmadi, T.
Moreau, P.
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14): : 1319 - 1331

← 1 2 3 4 5 →